Stone Summit Wealth LLC Sells 2,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Stone Summit Wealth LLC trimmed its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 15.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,020 shares of the company’s stock after selling 2,000 shares during the period. Stone Summit Wealth LLC’s holdings in Teva Pharmaceutical Industries were worth $185,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TEVA. US Bancorp DE increased its holdings in Teva Pharmaceutical Industries by 6.5% during the 1st quarter. US Bancorp DE now owns 10,812 shares of the company’s stock worth $166,000 after purchasing an additional 656 shares in the last quarter. Bfsg LLC increased its holdings in Teva Pharmaceutical Industries by 7.8% during the 1st quarter. Bfsg LLC now owns 10,960 shares of the company’s stock worth $168,000 after purchasing an additional 790 shares in the last quarter. Factorial Partners LLC increased its holdings in Teva Pharmaceutical Industries by 0.3% during the 1st quarter. Factorial Partners LLC now owns 333,000 shares of the company’s stock worth $5,118,000 after purchasing an additional 1,000 shares in the last quarter. Yousif Capital Management LLC increased its holdings in Teva Pharmaceutical Industries by 1.9% during the 1st quarter. Yousif Capital Management LLC now owns 55,986 shares of the company’s stock worth $861,000 after purchasing an additional 1,033 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its stake in shares of Teva Pharmaceutical Industries by 4.1% in the 4th quarter. Mackenzie Financial Corp now owns 29,889 shares of the company’s stock worth $659,000 after buying an additional 1,171 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on TEVA. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a “buy” rating and a $24.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $25.14.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider owned 6,774 shares in the company, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $18.30 on Friday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The business’s 50 day simple moving average is $17.77 and its 200 day simple moving average is $16.70. The company has a market cap of $20.99 billion, a price-to-earnings ratio of -114.38, a PEG ratio of 1.07 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.Teva Pharmaceutical Industries’s revenue for the quarter was up .3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.